Receptor, Cannabinoid, CB1, antagonists & inhibitors

Name
Receptor, Cannabinoid, CB1, antagonists & inhibitors
Accession Number
DBCAT001661
Description

Not Available

Drugs
DrugDrug Description
SLV319Investigated for use/treatment in obesity.
RimonabantFor use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated...
IbipinabantIbipinabant has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
SurinabantSurinabant has been investigated for the treatment of Smoking Cessation.
WIN 55212-2WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It...
OtenabantOtenabant has been investigated for the treatment of Obesity.
Drugs & Drug Targets
DrugTargetType
SLV319Cannabinoid receptor 1target
RimonabantCannabinoid receptor 1target
RimonabantCytochrome P450 3A4enzyme
RimonabantG-protein coupled receptor 55target
WIN 55212-2Cytochrome P450 3A4enzyme
OtenabantCannabinoid receptor 1target